Amy Michele Barreras is a pharmacist who is specialized in Oncology in Tampa, Florida. Patients can reach her at 12902 Usf Magnolia Dr, Tampa or contact her on 813-745-2888. Active license number of Amy Michele Barreras is PS42087 for Oncology in Florida. Amy Michele Barreras is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Amy Michele Barreras speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Amy Michele Barreras
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
12902 Usf Magnolia Dr, Tampa, Florida, 33612-9416
Phone:
813-745-2888
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Amy Michele Barreras are as mentioned below.
NPI Number:
1942297155
NPI Enumeration Date:
03 Oct, 2005
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Amy Michele Barreras are as mentioned below.
Specialization
License Number
State
Status
Oncology
PS42087
Florida
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
2009 Fruitridge St, Brandon, Florida
Zip:
33510-6008
Phone Number:
813-746-4691
Fax Number:
--
Patients can reach Amy Michele Barreras at 12902 Usf Magnolia Dr, Tampa, Florida or can call on phone at 813-745-2888.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 September, 2024.